Antibiotics – intravenous / inhalation (Various) – Cystic fibrosis

NICE recommendations, summary of meeting discussions, links to additional supporting docs etc.

This includes the IV antibacterial drugs:

Amikacin, Azteronam, Ceftazidime, Cefotaxime, Cefoxitin, Ceftriaxone, Co-Amoxiclav, Colistin, Flucloxacillin, Gentamicin, Meropenem, Piperacillin, Tobramycin.

July 2012: The TAG noted a draft General policy on the treatment of adults and children with Cystic Fibrosis, from the Specialised Commissioning Group (SCG) / East of England Priorities Advisory Committee (PAC) which does not include management of bronchiectasis. National treatment centre is in Birmingham. Drug treatments not included in the contract but are provided in-tariff by local acute trusts.

April 2013: NHS England SCG took over commissioning responsibility for these treatments.

September 2015: The TAG noted NG 15 (August 2015) Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use which covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.

October 2015:

Noted by the Norfolk & Waveney CCGs’ Drugs & Therapeutics Commissioning Group (D&TCG).

November 2017:

The TAG acknowledged NICE NG 78 (October 2017) – Cystic fibrosis: diagnosis and management